scholarly journals Catheter Directed Thrombolysis for Treatment of Ilio-femoral Deep Venous Thrombosis is Durable, Preserves Venous Valve Function and May Prevent Chronic Venous Insufficiency

2005 ◽  
Vol 30 (5) ◽  
pp. 556-562 ◽  
Author(s):  
H. Sillesen ◽  
S. Just ◽  
M. Jørgensen ◽  
N. Bækgaard
2019 ◽  
Vol 6 (8) ◽  
pp. 2698
Author(s):  
Mostafa A. Elaggory ◽  
Mahmoud S. Eldesouky ◽  
Nehad A. Zeid

Background: It was found that 50% of patients with iliofemoral deep venous thrombosis (DVT) treated by anticoagulant alone and compression stocking developed post thrombotic syndrome (PTS). Accelerated removal of thrombus by thrombolytic agents may increase venous patency and prevent PTS. The objective of the study was to assess short-term efficacy of additional catheter directed thrombolysis (CDT) compared with standard anticoagulant therapy alone.Methods: Prospective, randomized, controlled study on 50 patients (18–75 years) with acute iliofemoral DVT and symptoms <21 days were randomized to receive additional CDT or standard anticoagulant therapy alone. After 6 months, vein patency and insufficiency (reflux) was assessed using duplex ultrasound by an investigator blinded to previous treatments.Results: Fifty patients were allocated additional CDT (n=25) or ACs alone (n=25). After CDT, grade III (complete) lysis was achieved in 17 (68%) and grade II (50%–90%) lysis in 5 patients (20%). One patient suffered major bleeding and two had clinically relevant bleeding related to the CDT procedure. After 6 months, iliofemoral patency was found in 17 (68%) in the CDT group vs. 8 (32%) controls, corresponding to an absolute risk reduction 36% (95% CI, p=0.002). Femoral venous insufficiency was found to be higher among the ACs group 11 patients (44%) vs. 7 patients (28%) in the CDT group.Conclusions: After 6 months, additional CDT increased iliofemoral patency from 32% to 68% and decreased venous insufficiency from 44% to 28%.


1993 ◽  
Vol 18 (5) ◽  
pp. 760-766 ◽  
Author(s):  
Charles C. Wolferth ◽  
Todd M. Gerkin ◽  
Hugh G. Beebe ◽  
David M. Williams ◽  
Jess R. Bloom

1993 ◽  
Vol 18 (5) ◽  
pp. 760-766 ◽  
Author(s):  
Todd M. Gerkin ◽  
Hugh G. Beebe ◽  
David M. Williams ◽  
Jess R. Bloom ◽  
Thomas W. Wakefield

Author(s):  
Laura-Lee Farrell ◽  
Deepak Nair ◽  
Ross Milner ◽  
David Ku

Over seven million Americans suffer from chronic venous insufficiency, secondary to valvular dysfunction, with few effective clinical therapies. Chronic Venous Insufficiency (CVI) is a painful and debilitating disease that affects the superficial and deep veins of the legs. After deep venous thrombosis, the vein valves leaflets become adherent, fold over, or are absorbed into the vein wall. Incompetent valves allow reflux and subsequent pooling of blood in the legs. The resultant CVI causes severe leg edema, skin breakdown, and possible gangrene. Current clinical therapies are only modestly effective and include vein stripping and ligation, valvuloplasty, vein valve transposition, and vein valve transplantation. Valvuloplasty is the most definitive of CVI treatment, though this surgical treatment is rarely performed due to its difficulty. The quest for a better solution continues.


2017 ◽  
Vol 21 (1) ◽  
Author(s):  
Wim Greeff ◽  
Ali Reza Dehghan-Dehnavi ◽  
Jacobus Van Marle

Background: Chronic venous insufficiency is an important complication following iliofemoral deep venous thrombosis. Early thrombus removal may preserve venous function and prevent this complication. This study represents the largest reported South African series of pharmacomechanical thrombolysis for iliofemoral deep venous thrombosis to date.Objective: To evaluate the long-term outcome following pharmacomechanical thrombolysis for proximal and extensive deep venous thrombosis in a private, specialist vascular unit.Methods: All patients who underwent pharmacomechanical thrombolysis for iliofemoral deep venous thrombosis between August 2009 and January 2016 were invited to return for clinical assessment and venous ultrasound. Clinical findings were recorded according to the Villalta score and clinical, etiology, anatomic and pathology (CEAP) classification. The quality of life (QoL) was assessed utilising the VEINES-QoL/Sym questionnaire, providing two scores per patient, one describing the QoL and the other symptom severity (Sym).Results: Thirty two patients (35 legs) were evaluated. There were 25 females and 7 males, with a mean age of 33.5 years (±14 years). The mean follow-up period was 31 months (range 3 months – 80 months). Results of the CEAP classification were C0 = 24 (75%), C1 = 1 (4%), C2 = 2 (6%), C3 = 2 (6%) and C4 = 3 (9%). Thirty-one (97%) patients had Villalta scores from 0 to 4, indicating no or mild evidence of venous disease. One patient (3%) had a Villalta score of 6, indicating post-thrombotic syndrome. The mean QoL score was 87% (±12) and the mean Sym score was 86% (±14). Twenty-four (75%) patients had no abnormality on ultrasound, with fibrosis the most observed abnormality.Conclusion: Most patients who had undergone pharmacomechanical thrombolysis for extensive iliofemoral deep venous thrombosis showed few significant clinical signs of chronic venous insufficiency, had excellent function on venous ultrasound and reported excellent QoL.


Sign in / Sign up

Export Citation Format

Share Document